Enlarge / Moderna pharmaceutical and biotechnology company’s CEO Stephane Bancel speaks during a session of the World Economic Forum annual meeting in Davos on January 18, 2023. Getty | Fabrice COFFRINI
Moderna CEO Stéphane Bancel on Monday pushed back on criticism of the company’s plans to raise the price of its mRNA-based COVID-19 vaccines by 400 percent, arguing that the billions of dollars in federal funding the company received played little role in the vaccine’s development.
Speaking at the Wall Street Journal Health Forum, Bancel suggested that the vaccine’s development is thanks to private investors and that the federal funding
→ Continue reading at Ars Technica